Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
View Scopus Profile
Nan Li
Assistant Professor
Radiation Oncology
https://orcid.org/0000-0001-5391-0532
h-index
1500
Citations
16
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
2014
2021
Research activity per year
Overview
Fingerprint
Network
Research output
(19)
Similar Profiles
(6)
Fingerprint
Dive into the research topics where Nan Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Tankyrase
100%
Liver Kinase B1 (LKB1)
50%
PARP Inhibitor (PARPi)
50%
Tankyrase Inhibitor
44%
Non-small Cell Lung Cancer (NSCLC)
35%
Poly(ADP-ribose)
33%
Poly(ADP-ribose) Polymerase
31%
Tumor Growth
30%
Tumorigenesis
30%
Radiotherapy
29%
RNF146
25%
Neoadjuvant Chemotherapy
25%
Family Protein
25%
EGFR mutation
25%
Angiomotin
25%
Protein-protein Interaction Network
25%
Proteomic Analysis
25%
Low-density Lipoprotein Receptor-related protein-1 (LRP1)
25%
Metabolic Homeostasis
25%
Human Epidermal Growth Factor Receptor 2-negative
25%
AMPK Signaling
25%
Trametinib
25%
Pexophagy
25%
Pathway Activation
25%
RAD50
25%
KRAS mutant
25%
Radiosensitization
25%
53BP1
25%
Breast Cancer Susceptibility Gene 1 (BRCA1)
25%
Inflammatory Breast Cancer
25%
Ubiquitin Variants
25%
Targeted Therapeutics
25%
Panitumumab
25%
Poor Clinical Outcomes
25%
Cell Cycle-dependent
25%
Resectable Lung Cancer
25%
Notch Pathway
25%
Pyruvate Kinase M2 (PKM2)
25%
Pathological Complete Response
22%
FOXK2
16%
Lung Cancer
15%
Reverse Phase Protein Array
15%
Phosphorylation
13%
Cancer Treatment
13%
Ubiquitination
13%
Human Cancer
13%
Cell Growth
12%
Immune Cell Targeting
12%
G2 Phase
12%
Triple Negative
11%
Biochemistry, Genetics and Molecular Biology
AMP-activated Protein Kinase
50%
Poly ADP Ribose Polymerase
46%
Homeostasis
36%
Ubiquitin Ligase
33%
Tumor Progression
32%
Ubiquitination
32%
Catenin
30%
Carcinogenesis
28%
Protein Interaction
28%
Phosphatase
25%
Posttranslational Modification
25%
Synapsin I
25%
Proteomics
25%
Phosphoproteomics
25%
Pexophagy
25%
LDL Receptor
25%
Dishevelled
25%
Lipoprotein Receptor-Related Protein
25%
CRISPR
25%
Cas9
25%
PKM2
25%
Proteome
25%
Protein Family
25%
AMPK Signaling
25%
Mitochondrial Dynamics
25%
Cell Cycle
25%
BRCA1
25%
Epidermal Growth Factor Receptor
25%
Notch
25%
ADP-ribosylation
25%
Tumor Suppressor Protein
22%
G2 Phase
16%
Cell Proliferation
16%
Downregulation
16%
Guide RNA
15%
Enzyme
13%
Acetylation
12%
Fibrinogen
12%
Protein Stability
12%
Phosphatidylinositol (3,4,5)-trisphosphate
12%
Tensin
12%
G1 Phase
12%
Sumoylation
12%
Chromosome 10
12%
Ubiquitin-Conjugating Enzyme
12%
Colon
12%
Adenosine Diphosphate Ribose
12%
Genome Editing
10%
Adenosine Diphosphate
10%
RING Finger Domain
9%
Medicine and Dentistry
Radiation Therapy
75%
Non Small Cell Lung Cancer
30%
Cancer Therapy
30%
Poly ADP Ribose Polymerase
25%
Gamma Urogastrone
25%
Chemoradiotherapy
25%
Epidermal Growth Factor Receptor 2
25%
Inflammatory Breast Cancer
25%
Immunotherapy
25%
Panitumumab
25%
Neoadjuvant Chemotherapy
25%
PARP Inhibitor
25%
Clustered Regularly Interspaced Short Palindromic Repeat
25%
Cas9
25%
Sensitization
25%
Neoplasm
20%
Cancer Cell
16%
Tankyrase Inhibitor
15%
Guide RNA
15%
In Vitro
12%
Immunocompetent Cell
12%
Immune Checkpoint Blockade
12%
Immune System
12%
Protein Microarray
10%
Radiosensitivity
10%
Toxicity
10%
Genome Editing
10%
Malignant Neoplasm
9%
Biological Marker
8%
Cancer
7%
Tissue Microarray
7%
Lung Cancer Cell Line
7%
Phosphoprotein
7%
Distant Metastasis
6%
Cytotoxic T-Cell
6%
Radiation-Induced Cancer
6%
Melanoma
6%
Tumor Antigen
6%
Cell Damage
6%
Tumor Cell
6%
Stromal Cell
6%
Ipilimumab
6%
Immunosurveillance
6%
Monotherapy
6%
Tumor Microenvironment
6%
Combination Therapy
6%
Cancer Treatment
6%
Immunity
6%
Immune Checkpoint Inhibitor
6%
Hormone Receptor
5%
